A previous study under similar conditions [54] reported that combined treatment with a PPARα agonist, fenofibrate, and an LXR agonist, T0901317, alleviated insulin resistance and improved glucose tolerance but dramatically exacerbated hepatic steatosis. The gene discussed is PPARA; the disease is Insulin resistance.